3 years 4.8
Extreme 4.8
18.75
5 years 4.8
Extreme 4.8
52.43
10 years 4.8
Extreme 4.8
52.43
Manager TitleAgeSince
Chief Operating Officer - 2025-08-27
Chief Tech/Sci/R&D Officer - -
Chief Tech/Sci/R&D Officer 57 2024-08-04
Date Insider Type Main position Quantity % Market Cap. Importance
8/29/25 Tender

Chief Technology Officer

222,423 0.5811%
8/29/25 Tender

Chief Executive Officer; Director

1,106,638 2.8914%
8/29/25 Tender

Chief Operating Officer

578,671 1.5119%
Change 5-day change 1-year change 3-year change Capi.($)
+0.20%-.--% - - 449M
-2.01%-7.86%+60.74%+70.97% 68.92B
+0.51%+6.26%+6.87%+59.53% 51.9B
+2.25%+6.21%+11.48%+40.44% 48.73B
+0.51%+1.51%+27.96%+31.43% 43.13B
+2.70%-3.66%+307.41%+547.01% 41.48B
+0.69%-3.44%+9.52%+96.59% 39.96B
+0.06%-2.02%+11.25%+43.27% 30.6B
-2.21%-10.09%+35.34%-0.73% 26.01B
-0.39%-6.92%-13.60%-14.40% 22.27B
Average +0.40%-4.58%+50.77%+97.12% 41.44B
Weighted average by Cap. +0.35%-4.28%+54.69%+104.13%
Logo iTeos Therapeutics, Inc.
iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is focused on the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes three clinical-stage programs targeting novel, validated immuno-oncology pathways. Its lead antibody product candidate, belrestotug, also known as EOS-448/GSK4428859A, is an antagonist of TIGIT, an immune checkpoint with multiple mechanisms of action. Its EOS-984, a potentially first-in-class small molecule, focused on a new mechanism in the adenosine pathway by targeting equilibrative nucleoside transporter 1, a dominant transporter of extracellular adenosine, expressed on intratumoral T cells, which allows adenosine entry into the cell, disturbing T cell metabolism, expansion, effector function, and survival. It is also developing EOS-215, a potential best-in-class monoclonal antibody which antagonizes the triggering receptor expressed on myeloid cells 2.
Employees
173
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
  1. Stock Market
  2. Stocks
  3. ITOS Stock